Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

by Kaze, A.D, Kim, S.C, Paik, J.M, Patorno, E., Zhuo, M.
Published 2022

Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries

by Hawley, C.E, Kim, S.C, Lauffenburger, J.C, Paik, J.M, Patorno, E., Wexler, D.J
Published 2022

The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States

by Bateman, B.T, Gray, K.J, Hernández-Díaz, S., Huybrechts, K.F, Patorno, E., Seely, E.W, Vine, S., Wood, M.E
Published 2022

Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

by Bessette, L.G, Brodovicz, K.G, Déruaz-Luyet, A., Glynn, R.J, Najafzadeh, M., Paik, J.M, Patorno, E., Pawar, A., Schneeweiss, S., Wexler, D.J
Published 2022

Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision makin...

by Ali, M.S, Bennett, D., Debray, T.P.A, Gokhale, M., Guo, J.(, Largent, J., Moga, D.C, Panaccio, M., Patorno, E., Sarri, G., Wen, X., Yuan, H., Zullo, A.R
Published 2022